Target Audience — Hematologists-oncologists, medical oncologists, oncology fellows, pharmacists, physician assistants, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced level involved in the care of patients with hematologic malignancies.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Explain the emerging role of chimeric antigen receptor (CAR) T-cell treatment as an option for patients with relapsed/ refractory blood cancer|
|•||Discuss treatment plans for patient care|
|•||Explain potential short- and long-term side effects and management|
|•||Identify patients who could potentially be treated with CAR therapy|
|•||Engage patients and caregivers in discussions on CAR T-cell therapies including beneﬁts, risks, and barriers to entry|
Commercial Support Acknowledgement — This activity is supported by educational grants from Celgene Corporation and Kite, a Gilead Company.
Provider — This activity is jointly provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.
Continuing Education for Physicians, Pharmacists, Nurse Practitioners, Nurses, and Social Workers
Physician Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live educational activity for a maximum of XX AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Pharmacist Credit Designation
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides XX contact hours (XX CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is XXXXXX
Nurse Practitioners Credit Designation
This activity is approved for XX contact hours of continuing education (which includes XX hours pharmacology) by the American Association of Nurse Practitioners. Activity ID #XXXXXX. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Ofﬁce of The Leukemia & Lymphoma Society National Ofﬁce under provider number CEP 5832 to award XX continuing education contact hours through the California Board of Registered Nursing. Instructions for Credit.
Social Work Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive XX CE clinical contact hours.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive XX CE clinical contact hours for this activity.
For questions, grievances, or assistance please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest
Before the activity, all faculty and everyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of all financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity and The Leukemia & Lymphoma Society do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CPE/CE activity during the past 12 months.
David L. Porter, MD, is on the Advisory Board for: Glenmark; Kite, A Gilead Company; and Novartis. Research Support for Novartis, receives royalty payments for patent licensed by Penn to Novartis and his wife is employed with Genentech as a Division Sales Manager for the Breast Cancer Group. He does intend to include either non-FDA-approved or investigational use for the following products/devices: CAR T cells for CLL
Steven Bair, MD, has nothing to disclose. He does intend to include either non-FDA-approved or investigational use for the following products/devices: We will discuss the results of the bb2121 BCMA CAR product. We will also discuss other cellular therapy products in development, but not approved for myeloma (to be determined).
Jacqueline C. Barrientos, MD, MS, is a Consultant for: AstraZeneca; Bayer; Genentech; Gilead Sciences, Inc.; Pharmacyclics, An AbbVie Company and Sandoz, Inc., a Novartis Division. Received an honorarium for a Medical Education Speaker Event for Janssen, Pharmaceutical Companies of Johnson & Johnson. She does intend to include either non-FDA-approved or investigational use for the following products/devices: novel agents currently on clinical trial for CAR T therapy.
Ira Braunschweig, MD, has nothing to disclose. He does not intend to include any non-FDA-approved or investigational use of any products/devices.
Adam D. Cohen, MD, is a Consultant for: Celgene Corporation; Janssen, Pharmaceutical Companies of Johnson & Johnson; Kite Pharma, A Gilead Company; Seattle Genetics; and Takeda. Research Support and Intellectual property related to CAR T cells licensed by University of Pennsylvania for Novartis. He does intend to include either non-FDA-approved or investigational use for the following products/devices: BCMA-directed CAR T cells for myeloma.
Dennis L. Cooper, MD, has nothing to disclose. He does intend to include either non-FDA-approved or investigational use for the following products/devices: novel agents currently on clinical trial for CAR T therapy.
Susan Dewolf, MD, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Heather DiFilippo, MSN, CRNP, has nothing to disclose. She does intend to include either non-FDA-approved or investigational use for the following products/devices: novel agents currently on clinical trial for CAR T therapy.
Sergio A. Giralt, MD, is a Consultant for: Amgen, Celgene Corporation, Jazz Pharmaceuticals, Johnson & Johnson, Sanofi, and Takeda. He does intend to include either non-FDA-approved or investigational use for the following products/devices: novel agents currently on clinical trial for CAR T therapy.
Sukhdeep Kaur, MD, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Jamie L. Koprivnikar, MD, is on the Speaker’s Bureau for: AbbVie, Alexion, Amgen, and Novartis. She does intend to include either non-FDA-approved or investigational use for the following products/devices: novel agents currently on clinical trial for CAR T therapy.
Deepu Madduri, MD, is a Consultant for Foundation Medicine and Takeda. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Nigina Mirazimova, MSN, RN, OCN®, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Gwen L. Nichols, MD, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Ran Reshef, MD, MSc, is on the Advisory Board for Atara Biotherapeutics and Pfizer. He is a Consultant for Kite, A Gilead Company and Magenta Therapeutics. He does intend to include either non-FDA-approved or investigational use for the following products/devices: CAR-T cells in off label indications.
Joanna M. Rhodes, MD, received a fee as a Medical Reviewer for Medscape. She does intend to include either non-FDA-approved or investigational use for the following products/devices: CJL-019 for CLL and CAR T for CLL.
Larysa Sanchez, MD, has nothing to disclose. She does intend to include either non-FDA-approved or investigational use for the following products/devices: CAR T in Multiple Myeloma.
Gunjan L. Shah, MD, has done Research Funding for Amgen and Janssen, Pharmaceuticals Companies of Johnson & Johnson. She does intend to include either non-FDA-approved or investigational use for the following products/devices: CAR T for non-FDA approved indications.
Mari Lynne Silverberg, MPA, RN, BSN, OCN®, has nothing to disclose. She does intend to include either non-FDA-approved or investigational use for the following products/devices: CAR T-cells/Immune Effector Cell.
Koen van Besien, MD, PhD- has does research support for AffyImmune Therapeutics and Consultant and on the Advisory Board for Cellectis. He does not intend to include any non-FDA-approved or investigational use of any products/devices.
Elizabeth A, Weber, BSN, RN, is a Consultant for Novartis. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Catherine Wei, MD, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Content Expert Reviewers Disclosures
Patricia Ensor, RPh, Content Expert Reviewer, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Teresa Haile, RPh, MBA, Lead Pharmacy Planner, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.
Disclaimer — The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
|Estimated time to complete activity: XX hours|
|Date of initial release: XXXX|
|Valid for CME credit through XXXX|
David L. Porter, MD, is the Jodi Fisher-Horowitz Professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center, and Director of the Blood and Marrow Transplantation and Cellular Therapeutics program at the Hospital of the University of Pennsylvania. He is a graduate of the University of Rochester and earned his medical degree at Brown University. He completed his internship and residency at Boston University Hospital, and fellowship training at Brigham and Women’s Hospital and Harvard Medical School in Boston.
He Chairs or serves on numerous local, national and international committees focused on hematologic malignancies, hematopoietic stem cell transplantation and cell therapy. He is the Vice Chair of the Board of Directors of the National Marrow Donor Program and a member of the American Board of Internal Medicine Hematology Exam Committee. Dr Porter is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Blood and Marrow Transplantation. He has authored more than 170 research articles and book chapters, is an Associate Editor for the American Journal of Hematology and has served as a manuscript reviewer for numerous high impact medical journals. He is the recipient of several prestigious awards at the University of Pennsylvania including recognition for Professionalism and Mentorship. He is annually recognized as a “Top Doc” in Philadelphia Magazine and Castle Connolly and has been the recipient of the Leukemia and Lymphoma Society Service to Mankind Award.
Dr. Porter has expertise in development of novel cellular therapies, in the care of patients with hematologic malignancies including acute and chronic leukemia, and in all aspects of hematopoietic SCT. He leads numerous local and national research activities. He is an accomplished clinical investigator with principal research interests in development of novel methods of cellular therapy, stem cell transplantation, and allogeneic adoptive immunotherapy. Dr. Porter has worked with colleagues at the University of Pennsylvania to pioneer successful development of CAR T cells (genetically modified T cells) to treat B cell cancers like ALL, NHL and CLL. Other research highlights include development of novel trials designed to prevent GVHD after allogeneic SCT by blocking lymphocyte trafficking, and studies to enhance graft-vs-tumor activity at the time of transplant, after non-myeloablative therapy, and for relapse after SCT.
Jacqueline C. Barrientos, MD, is Attending Physician at the Chronic Lymphocytic Leukemia (CLL) Research & Treatment Program of the Division of Hematology and Medical Oncology, Department of Medicine, the Northwell Health Cancer Institute in Lake Success, New York. She is Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Dr. Barrientos received her medical degree at the Ponce School of Medicine where she was the recipient of two Howard Hughes Medical Institute Fellowship award. She completed her internship and residency in internal medicine at Yale-New Haven Hospital of the Yale School of Medicine, and her fellowship in Hematology/Oncology at Weill Cornell Medical College in New York City, where she also served as Chief Fellow and completed a Masters degree in Clinical Investigation at the Weill Cornell Graduate School of Medical Sciences. She is board certified in hematology and oncology. S Dr. Barrientos is Principal Investigator on several clinical trials involving targeted agents. She has received several awards including the American Society of Hematology Harold Amos Medical Faculty Development Program Award and the Paul Foundation Innovation Award.
Adam D. Cohen, MD received his medical degree and did his internal medicine residency at the University of Pennsylvania, Philadelphia. He completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center, New York, including research training in the Laboratory of Tumor Immunology under Alan Houghton, MD. He then served as faculty on the Hematology Service at Fox Chase Cancer Center, Philadelphia. Currently, he is Director of Myeloma Immunotherapy, and an Assistant Professor of Medicine at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Dr. Cohen is board certified in medical oncology and hematology. He is a member of ASCO, ASH, and AACR. He is also a member of the Multiple Myeloma Committee, Eastern Cooperative Oncology Group, and has served on the NCCN Multiple Myeloma Guidelines Panel. He is a medical advisor for the Myeloma Beacon, and an ad hoc reviewer for Leukemia, Blood, and Clinical Cancer Research, among other journals. His research interests involve novel therapeutics for plasma cell diseases, particularly vaccines and cellular immunotherapies. He has co-authored over 50 original articles, chapters, and reviews on cancer vaccines, tumor immunity, multiple myeloma, amyloidosis, and stem cell transplant.
Dennis L. Cooper is the Medical Oncologist and Chief Section of the Blood and Marrow Transplant Program, Professor of Medical Oncology at Rutgers Cancer Institute, and an Attending Physician at Robert Wood Johnson University Hospital. Dr. Cooper spent more than 30 years at Yale Cancer Center and became the Director of the Yale Stem Cell Transplant Program in 1997 and remained in that position for over 17 years. His major areas of clinical expertise are multiple myeloma, Hodgkin lymphoma, non Hodgkin lymphoma disease. His proudest accomplishment is the World Series victory of the Chicago Cubs.
Heather DiFilippo MSN, CRNP, is a nurse practitioner in the Department of Hematology Oncology and Bone Marrow Transplant at the Hospital of the University of Pennsylvania. She has been a nurse practitioner since 2003 and specializes in hematologic malignancies as well as bone marrow transplant and immunotherapy. She has played an active role in managing patients receiving cellular therapy since 2009, and provides ongoing patient education as well as direct patient care during and after infusion. Ms. DiFilippo attended Roanoke College in Salem, Virginia where she received a Bachelor of Science in psychology, before continuing on to pursue a Bachelor of Science in nursing at Thomas Jefferson University Hospital. While working in oncology at Jefferson University Hospital, she completed her Master of Science in nursing as well. Ms. DiFilippo is a Board Certified Adult Nurse Practitioner and licensed in Pennsylvania.
Sergio A. Giralt, MD is the Chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center in New York. He is affiliated with Weill Cornell Medical College as a Professor of Medicine. He received his medical degree from Universidad Central de Venezuela in Caracas, Venezuela, and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center.
Board Certified in internal medicine and hematology, Dr. Giralt holds membership in several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology, the North American Society of Blood and Bone Marrow Transplantation, and the International Society of Hematology. He holds key positions with several organizations including the International Bone Marrow Transplant Registry Executive Committee, the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) Steering Committee, the National Marrow Donor Program Board of Directors, and the Clinical Advisory Board of the Web site, Managing Myeloma. He is the past President of the American Society for Blood and Marrow Transplantation as well as the Past Chair of the BMT-CTN and the Center for International Blood and Marrow Transplant Research.
Dr. Giralt’s clinical research career has focused in three areas
1) Developing better tolerated conditioning regimens for older or medically infirmed patients with hematologic malignancies to allow them access to this procedure
2) Developing novel HCT therapies (conditioning regimens plus post transplant therapies) for autologous and allogeneic HCT for myeloma
3) Pursuing strategies that will significantly reduce HCT symptom burden and toxicities
As Chief of the Adult BMT Service, he has had extensive experience designing, implementing, and performing HCT studies both as a principal investigator and as a collaborator.
Dr. Giralt has published over 400 articles and abstracts in the peer-reviewed literature and written chapters for several books. Additionally, Dr. Giralt is a reviewer and editorial board member for several journals.
Jamie L. Koprvinikar, MD, specializes in hematology and medical oncology and is board certified in both. She also holds a board certification in internal medicine.
Dr. Koprivnikar received her medical degree from the Sidney Kimmel Medical College, formerly Jefferson Medical College of Thomas Jefferson University, in Philadelphia, PA. She completed her internal medicine residency at MedStar Georgetown University Medical Center in Washington, DC. She then completed a fellowship in hematology and oncology, also at MedStar Georgetown University Medical Center. She was chosen to serve as chief fellow during her third and final year of fellowship.
Dr. Koprivnikar spent the early part of her career on faculty at MedStar Georgetown University Medical Center where she was active in teaching medical students, residents, and fellows. She also served as the medical co-director of the Patient Blood Management Program and was active on the institutional review board and as an investigator on many clinical trials. She is a member of the American Society of Hematology.
In her current practice, at the John Theurer Cancer Center, she focuses on leukemias, myelodysplastic syndrome and other bone marrow failure disorders such as aplastic anemia and paroxysmal nocturnal hemoglobinuria. She is an active investigator on numerous clinical trials.
Deepu Madduri, MD, is an Assistant Professor of Medicine in the Multiple Myeloma Program at Mt. Sinai Hospital in New York, NY. She is also an oncology consultant at Foundation Medicine, Inc., a cancer genomic company, and lead their Smart Trials Precision enrollment program.
Dr. Madduri specializes in plasma cell disorders including multiple myeloma, amyloid light-chain (AL) amyloidosis, POEMS syndrome, plasmacytoma and monoclonal gammopathies of uncertain significance (MGUS). She performs a variety of procedures including bone marrow biopsy, and stem cell transplant. Dr. Madduri serves as the lead physician liaison between the Multiple Myeloma Program and the Bone Marrow Transplant Program at Mt. Sinai Hospital which has significantly eased the transition in between the two departments for the patients undergoing an autotransplant.
Her research interests include immunotherapy with checkpoint inhibitors, and immune effector cells such as Car-T therapy, NK-cell therapy, and Bi-specific antibodies.
Dr. Madduri received her medical degree from the University of Oklahoma School of Medicine in Oklahoma City, Oklahoma. She completed her residency in internal medicine at St. Mary Medical Center and a fellowship in Hematology and Oncology at the University of California, Harbor Campus in Torrance, California. She did another fellowship in Blood and Marrow Transplant at Stanford Hospital; and received her undergraduate degree from the University of Oklahoma.
Nigina Mirazimova, MSN, RN, OCN® is the Patient Care Director of the Outpatient Oncology at NYP/WC. In her role, she oversees Adult and Pediatric Infusion Centers, Apheresis and Bone Marrow Transplant Department. Before this role, she oversaw clinical operations of the Infusion Suite at Maimonides Cancer Center. Nigina holds a master’s in nursing with Adult Gerontology Nurse Practitioner and Adult Clinical Nurse Specialist degree. Currently, she is pursuing the Doctoral in Nursing Practice degree.
Ran Reshef, MD, MSc, is the Director of Translational Research in the Blood and Marrow Transplantation and Cell Therapy Program at Columbia University Medical Center. He is the clinical lead of the CAR-T cell program for both commercially available CAR-T and experimental cell therapies that are still in clinical trials. He directs a research lab in the Columbia Center for Translational Immunology and he is a member of the Herbert Irving Comprehensive Cancer Center.
Dr. Reshef’s research revolves around immunotherapy approaches for the treatment of cancer and his lab studies novel ways to improve the efficacy and the safety of immunotherapies including bone marrow transplants, checkpoint inhibitors and CAR-T cells. He has authored or co-authored more than 60 original research publications related to cancer and bone marrow transplantation and has received research funding from the Leukemia and Lymphoma Society, National Cancer Institute, Conquer Cancer Foundation, Department of Defense, National Marrow Donor Program and the American Society of Hematology.
Gunjan Shah, MD received her MD at Temple University School of Medicine in 2008. She completed her internal medicine residency training at Thomas Jefferson University Hospital, hematology/oncology fellowship at Tufts Medical Center, and BMT fellowship at Memorial Sloan Kettering Cancer Center. Dr. Shah joined Memorial Sloan Kettering Cancer Center in 2016 as an Assistant Attending and is part of the Adult BMT Service and the Center for Health Policy and Outcomes. Dr. Shah`s research has focused on improving access, tolerability, and outcomes for patients with lymphoma and myeloma undergoing autologous and allogeneic stem cell transplantation and CAR T cells, as well as comparative and cost effectiveness of treatments for the hematologic malignancies.
Mari Lynne Silverberg, MPA, RN, BSN, OCN®, has been involved in Oncology nursing for the last 30 years, being a Certified Oncology Nurse for the last 25. She has cared for patients as a staff nurse in both the inpatient and outpatient settings, and held leadership positions throughout her career, with a concentration on office practice and infusion.
During one of her positions while she was responsible for a busy Hematology-Oncology and Gynecological Oncology Office Practice and Infusion Center, Mari Lynne was also tapped to become a quality officer for the Bone Marrow Transplant Program supported by her units. This role afforded her the opportunity to learn BMT from the inside out, to prepare and participate in FACT inspections and lead quality initiatives through audit findings and patient reviews. She flourished in the role.
Mari Lynne’s current position as a Senior Quality Management Nurse at Memorial Sloan-Kettering Cancer Center allows her to utilize her leadership skills, clinical background and quality experience to establish policies, procedures, quality metrics, education programs and processes to continue to build the Center’s Immune Effector Cell program. She has assisted in creating various nursing and patient-care documents, as well planning and executing the REMS training (Risk Evaluation Mitigation Strategies) trainings required by the FDA for commercial CAR T cells for over 400 applicable staff, while supporting and completing other infrastructure needs.
Mari Lynne continues to enjoy her integral role in MSK’s Cellular Therapy program, as well as in preparing this program and the HSCT program for regulatory inspections, participating in ongoing quality reviews and initiatives and providing other support as necessary.
Koen van Besien, MD, PhD, is a graduate of the College ND de la Paix in Namur, Belgium and from the University of Leuven, Belgium where he also did his clinical training in Medicine. He holds a PhD from the University of Maastricht in the Netherlands. He did a hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Afterwards he was on the faculty in the transplant program at MD Anderson Cancer Center in Houston Texas. He directed the Transplant program at the University of Illinois from 1997 until 2001 and the Transplant and Lymphoma programs at the University of Chicago from 2001 until 2011.
Dr. van Besien is the Director of the Stem Cell Transplant Program, a Professor of Medicine at Weill Cornell Medical College and Attending Physician at the New York-Presbyterian Hospital.
Dr. van Besien has established a national and international reputation with several research and clinical interests. He has devoted considerable efforts at developing novel treatment strategies for patients with recurrent lymphoma, including the introduction of novel drugs and treatment in salvage therapy and in transplant conditioning regimens. He also has developed novel methods of transplantation for those patients who lack matching donors. Most recently his group has described a novel concept of haplo-cord transplantation with extremely encouraging results.
Dr. van Besien has over 210 publications in peer reviewed journals and his research continues to be supported by NIH. He is a member of the editorial review boards of the journals Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He is also Editor in Chief of the journal Leukemia and Lymphoma.
Dr. van Besien oversees the transplant program at Weill Cornell Medical College/New York Presbyterian Hospital. Deciding on stem cell, umbilical cord or bone marrow transplant is complex. One’s care involves a large number of health care professionals and a team approach. Weill Cornell Medical College/New York Presbyterian Hospital has world class facilities and a transplant team that provides superb care and has access to the latest clinical research. We are lucky to have renowned leukemia, lymphoma and myeloma experts who are intimately involved in the decision process. New York Presbyterian is consistently ranked among the very best hospitals in the nations. If complications arise, we can therefore count on the help of some of the best experts in a variety of disciplines including infectious diseases, pulmonary, gastro-enterology.
Elizabeth (Lizzie) Weber, BSN, RN is the Commercial Cellular Therapy Coordinator at Penn Medicine. She received her nursing degree from Widener University. She graduated with Honors and was the recipient of the Pediatric Excellence in Care Award as well as the Undergraduate Nursing Research Award. She spent the start of her nursing career as an inpatient nurse on a Neuroscience Medical-Surgical Floor at the Hospital of the University of Pennsylvania. During this time, she was awarded “Neuroscience Nurse of the Year” and served as Unit Council Chair for a two-year term.
In her current role, Lizzie collaborates with leadership to establish organizational systems to safely provide patient care for cellular therapy candidates. She coordinates complex care for cellular therapy recipients (actual or potential) as patients navigate through the evaluation of, preparation for and care post cellular therapy infusion. She provides ongoing patient/family education based on evaluation of the individual needs of patients/families. She also participates in collaborations with manufacturers, professional organizations and other institutions to disseminate information regarding lessons learned operationalizing a Commercial Cellular Therapy Program.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
CART specific resources: www.LLS.org/CART
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Additional support resources: www.LLS.org/support
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with clinical trial specialists who are registered nurses with expertise in blood cancers. RNs will personally assist through the clinical trial process, providing an additional resource to your HCP team.